**Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis**

Tadashi Nakamura

[125] Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infec‐ tion in HBsAg- negative patients undergoing cytotoxic chemotherapy. Gastroenterol‐

[126] Kuroda T, Kobayashi D, Sato H, et al. Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: A review of the literature.

[127] Kishida D, Okuda Y, Onishi M, Takebayashi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Takasugi K. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A

[128] van Gameren II, Hazenberg BP, Bijzet J, Haagsma EB, Vellenga E, Posthumus MD, Jager PL, van Rijswijk MH. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Artritis Care Res (Hoboken). 2010;62(3) 296-301.

[129] Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, Fukuda J. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol. 1994;21(1) 33–

[130] Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and

[131] Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford). 2012 Sep 22, doi:10.1093/rheuma‐

[132] Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M; Immunopathology Group of the Italian Society of Nephrology. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant.

[133] Bollée G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol. 2008;3(2)

[134] Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart. Arch Intern Med 2006;

[135] Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;

prognostic markers in AA amyloidosis. QJM. 2000;93(8) 535–542.

ogy. 2006;131(1) 59-68.

36.

212 Amyloidosis

tology/kes244.

2008;23(3) 941-951.

166(17) 1805-1813.

112(13) 2047-2060.

375-381.

Rheumatol Int. 2012;32(4) 1059-1063.

amyloidosis. Mod Rheumatol. 2011;21(2) 215-218.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53801

## **1. Introduction**

Amyloidosis is a disorder of protein conformation and metabolism that results in the depo‐ sition of insoluble amyloid fibrils in tissues, which causes organ dysfunction; systemic amy‐ loidosis is characterized by failure of multiple organs and the presence of amyloid precursor protein in the serum [1-3]. Reactive amyloid A (AA) amyloidosis is one of the most severe complications of several chronic disorders, particularly rheumatoid arthritis (RA) [4], and indeed, most patients with reactive AA amyloidosis have an underlying rheumatic disease. An extra-articular complication of RA, AA amyloidosis is a serious, potentially life-threaten‐ ing disorder caused by deposition in organs of AA amyloid fibrils, which derive from the circulatory acute-phase reactant, serum amyloid A protein (SAA) [5]. AA amyloidosis sec‐ ondary to RA is thus one of the intractable conditions found in patients with collagen vascu‐ lar diseases and is an uncommon yet important complication of RA [6]. However, the actual pathological mechanisms that are responsible for the relationship between SAA and AA amyloidosis have not been fully elucidated.

With new biological therapies, both treatment and understanding of the roles of cytokines and inflammatory cellular events in RA have seen considerable progress. Biologics are rec‐ ommended for patients with RA who have a suboptimal response or an intolerance to tradi‐ tional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX). Early diagnosis and rapidly subsequent treatment are essential because patients with ad‐ vanced disease can't usually undergo intensive therapy. Specific treatment of AA amyloido‐ sis caused by RA aims to stop SAA production. Cytotoxics such as chlorambucil and cyclophosphamide (CYC) and biologics such as anti-tumor necrosis factor (TNF)α inhibitors and anti-interleukin (IL)-6 receptor antibody are reportedly useful for both RA and AA amyloidosis [7, 8]. By the way, the genetic predisposition allele SAA1.3, one of SAA1 gene

© 2013 Nakamura; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

polymorphism, can serve not only as a risk factor for the association of AA amyloidosis, but also as a poor prognostic factor in Japanese RA patients [9]. Both the association of AA amy‐ loidosis arising early in the RA disease course and symptomatic variety and severity were found in amyloidotic patients carrying SAA1.3 allele. Etanercept (ETN) for patients with AA amyloidosis secondary to RA, who carry SAA1.3 allele, showed the amelioration of rheuma‐ toid inflammation, including marked reduction of SAA, improvement of proteinuria and creatinine clearance [10], that would demonstrate efficacy and safety even in patients under‐ gone on hemodialysis [11]. These lead us to the notion of clinical significance of SAA1.3 al‐ lele in the clinical strategy of Japanese RA patients.

This article will discuss on therapeutic strategies from the point of biologics view on RA treatment in relation to AA amyloidosis secondary to RA based on our reports and literature reviews.

## **2. Significance of SAA1.3 allele genotype in Japanese RA patients with AA amyloidosis**

**Figure 1.** SAA1.3 allele frequency and AA amyloidosis in Japanese RA patients. SAA1.3 allele is associated with in‐ creased risk of AA amyloidosis in Japanese RA patients. Figures are courtesy of Satoshi Baba, MD and modified from

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

215

**Figure 2.** Kaplan-Meier survival curve in RA disease course for RA patients with (continuous line) and without (dotted

line) SAA1.3/1.3 (P=0.015, log-rank test) from Reference No. 9.

Reference No. 12.

It was reported that the frequency of SAA1.3 allele was markedly increased in AA amyloi‐ dosis in Japanese RA patients (Fig. 1), suggesting that this allele was a risk factor for AA amyloidosis secondary to RA [12]. That is, SAA1.3 allele has been reported to be associated with increased risk of AA amyloidosis and SAA1.1 with decreased risk [13], while SAA1.1 was revealed to be a risk factor for developing AA amyloidosis in the Caucasian population [14]. We calculated the hazard ratio in the presence or absence of SAA1.3/1.3 homozygosity as a survival parameter after the onset of RA. By means of Cox proportional hazard survival analysis, carrying with SAA1.3/1.3 homozygosity was statistically significant for survival (*P*=0.015) with hazard ratio of 2.101 (95% CI: 1.157 - 3.812). Also, the Kaplan-Meier curve showed a significant difference during observation from diagnosis of RA (Fig. 2). The mean survival period of the all patients with and without SAA 1.3/1.3 was 6.52±6.18 years and 13.8±8.47 years, with 43.8% and 71.6% surviving for 10 years, respectively. The SAA1.3 al‐ lele, particularly homozygosity for SAA1.3, was a univariate predictor of survival. The pre‐ senting factors which adversely influenced clinical outcome after diagnosis of AA amyloidosis were age (*P*=0.001), raised serum creatinine (Crea) concentration (*P*=2.14 X 10-5), lowered serum albumin (Alb) concentration (*P*=0.001), and presence of SAA1.3/1.3 (*P*=0.035). While, after diagnosis of RA, age of RA onset (*P*=2.95 X 10-4) and presence of renal involve‐ ment (*P*=0.011) were extracted as survival parameter. The serum Crea value of >2.5mg/dl upon diagnosis of AA amyloidosis was closely related with poorer survival, when com‐ pared with a serum Crea value of ≦2.5mg/dl by Kaplan-Meier technique (*P*=0.013 with logrank statistic) (Fig. 3). The presence of cardiac involvement was likely to be a risk factor to survival (*P*=0.062). These results have revealed the significance of SAA1.3 allele genotype in Japanese RA patients with AA amyloidosis when we follow-up such patients in daily prac‐ tice [15, 16]. However, we just need more studies about the large prospective trials to prove the usefulness of SAA1.3 allele genotype.

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis http://dx.doi.org/10.5772/53801 215

polymorphism, can serve not only as a risk factor for the association of AA amyloidosis, but also as a poor prognostic factor in Japanese RA patients [9]. Both the association of AA amy‐ loidosis arising early in the RA disease course and symptomatic variety and severity were found in amyloidotic patients carrying SAA1.3 allele. Etanercept (ETN) for patients with AA amyloidosis secondary to RA, who carry SAA1.3 allele, showed the amelioration of rheuma‐ toid inflammation, including marked reduction of SAA, improvement of proteinuria and creatinine clearance [10], that would demonstrate efficacy and safety even in patients under‐ gone on hemodialysis [11]. These lead us to the notion of clinical significance of SAA1.3 al‐

This article will discuss on therapeutic strategies from the point of biologics view on RA treatment in relation to AA amyloidosis secondary to RA based on our reports and literature

**2. Significance of SAA1.3 allele genotype in Japanese RA patients with**

It was reported that the frequency of SAA1.3 allele was markedly increased in AA amyloi‐ dosis in Japanese RA patients (Fig. 1), suggesting that this allele was a risk factor for AA amyloidosis secondary to RA [12]. That is, SAA1.3 allele has been reported to be associated with increased risk of AA amyloidosis and SAA1.1 with decreased risk [13], while SAA1.1 was revealed to be a risk factor for developing AA amyloidosis in the Caucasian population [14]. We calculated the hazard ratio in the presence or absence of SAA1.3/1.3 homozygosity as a survival parameter after the onset of RA. By means of Cox proportional hazard survival analysis, carrying with SAA1.3/1.3 homozygosity was statistically significant for survival (*P*=0.015) with hazard ratio of 2.101 (95% CI: 1.157 - 3.812). Also, the Kaplan-Meier curve showed a significant difference during observation from diagnosis of RA (Fig. 2). The mean survival period of the all patients with and without SAA 1.3/1.3 was 6.52±6.18 years and 13.8±8.47 years, with 43.8% and 71.6% surviving for 10 years, respectively. The SAA1.3 al‐ lele, particularly homozygosity for SAA1.3, was a univariate predictor of survival. The pre‐ senting factors which adversely influenced clinical outcome after diagnosis of AA amyloidosis were age (*P*=0.001), raised serum creatinine (Crea) concentration (*P*=2.14 X 10-5), lowered serum albumin (Alb) concentration (*P*=0.001), and presence of SAA1.3/1.3 (*P*=0.035). While, after diagnosis of RA, age of RA onset (*P*=2.95 X 10-4) and presence of renal involve‐ ment (*P*=0.011) were extracted as survival parameter. The serum Crea value of >2.5mg/dl upon diagnosis of AA amyloidosis was closely related with poorer survival, when com‐ pared with a serum Crea value of ≦2.5mg/dl by Kaplan-Meier technique (*P*=0.013 with logrank statistic) (Fig. 3). The presence of cardiac involvement was likely to be a risk factor to survival (*P*=0.062). These results have revealed the significance of SAA1.3 allele genotype in Japanese RA patients with AA amyloidosis when we follow-up such patients in daily prac‐ tice [15, 16]. However, we just need more studies about the large prospective trials to prove

lele in the clinical strategy of Japanese RA patients.

the usefulness of SAA1.3 allele genotype.

reviews.

214 Amyloidosis

**AA amyloidosis**

**Figure 1.** SAA1.3 allele frequency and AA amyloidosis in Japanese RA patients. SAA1.3 allele is associated with in‐ creased risk of AA amyloidosis in Japanese RA patients. Figures are courtesy of Satoshi Baba, MD and modified from Reference No. 12.

**Figure 2.** Kaplan-Meier survival curve in RA disease course for RA patients with (continuous line) and without (dotted line) SAA1.3/1.3 (P=0.015, log-rank test) from Reference No. 9.

the marked geographic differences are unclear. The difference in the frequency of AA amy‐ loidosis among different races, and the fact that AA amyloidosis is not consistently related to the length and severity of chronic inflammation suggests that AA amyloidosis may be, at

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

217

The principal aim in treating RA patients with AA amyloidosis is to switch off SAA produc‐ tion by controlling the RA inflammatory process. Anti-inflammatory treatment must be em‐ pirical but, as in all patients with AA amyloidosis, should be guided by frequent assessment of SAA concentrations in view of reported correlations between survival and this measure. Treatment of AA amyloidosis secondary to RA may involve the following strategies as out‐

(2)Evaluate renal function by the levels of eGFR4), cystatin C, and Ccr5)

(4)Detect AA amyloid fibrils with organ biopsy like GI tracts, labia, and abdominal

(5)Require renal biopsy in cases with proteinuria or renal dysfunction in RA patients

(iii) Choose MTX9) plus biologics in cases uncontrollable from early phase

(3)Steroid, codeine phosphate, lactate bacteriae, and especially octreotide for refractory

(4)Stand on the notion of deposited AA amyloid fibrils existing in a state of dynamic turnover

(iv) Challenge new biologics and signal transduction inhibitors

1)AA:amyloid A, 2)RA:rheumatoid arthritis, 3)SAA:serum amyloid A protein, 4)eGFR: estimated glomerular filtration rate, 5)Ccr:creatinine clearance, 6)GI:gastrointestine, 7) T2T: treat RA to target, 8) HD:hemodialysis,9)MTX:methotrexate

(ii) Control RA disease tightly according to T2T7) recommendations even in patients

(2)Keep the serum levels of SAA3)less than 10 μg/ml (3)Control tightly rheumatoid inflammatory responses (4)Follow-up RA patients carrying SAA1.3 allele carefully

least in part, influenced by genetic factors [23-25].

**Prevention** (1)Be careful not to raise AA amyloidosis

**Diagnosis** (1)Do not underestimate proteinuria

subcutaneous fat

diarrhea

(3)Watch GI6) tract symptoms

undergoing HD8)

**Table 1.** Clinical strategies in the management of AA1) amyloidosis secondary to RA2)

**Therapy:** (1)Control acute-phase responses to suppress the synthesis of SAA (2)Control RA disease activity tightly

(i) Do not lose window of opportunity

lined in Table 1 [26].

**4. Treatments of AA amyloidosis secondary to RA**

**Figure 3.** Kaplan-Meier survival curve after diagnosis of AA amyloidosis for patients with serum creatinine >2.5mg /dl (continuous line) and serum creatinine ≦2.5mg/dl (dotted line) (P=0.013, log-rank test) from Reference No. 9.

#### **3. Fundamental thoughts for therapies**

According to the information on the studies using radiolabelled human serum amyloid component P (SAP) as a specific quantitative *in vivo* scintigraphic tracer for monitoring of systemic AA amyloidosis [17], treatments those effectively suppress production of SAA halt the progressive accumulation of AA amyloid deposits and, in many cases, they are associat‐ ed with AA amyloid regression, improved organ function and survival [18, 19]. AA amyloid deposits are evidently turning over, their net size reflecting the balance of deposition and regression [20]. Therefore, AA amyloid deposits may regress at a low rate over a period of years and exist in a sate of dynamic turnover. The usual clinical impression of inexorable progression of AA amyloidosis actually reflects the progressive and usually incurable na‐ ture of the underlying primary condition, which is complicated by AA amyloidosis. Howev‐ er, new and aggressive approaches to therapy, such as cytotoxic anti-inflammatory drugs and biologic agents in chronic rheumatic inflammation, will lead to impressive AA amyloid regression and prolonged survival. Unfortunately these treatments do not always work and there are many difficult cases in those approaches are neither possible now nor likely to be‐ come feasible in future. In view of clinical significance of AA amyloidosis, there is an urgent need to facilitate studies into this complication. Early diagnosis and intervention are essen‐ tial for RA, however, few specific features are useful for diagnosis of RA and its diagnosis is often difficult in daily RA practice. Reduction of SAA load is currently the most rational ap‐ proach thereby arresting further deposition [21]. It is not exactly known why some patients develop a progressive AA amyloidosis while others do not, although latent deposits may be present. While there is startling variation in the frequency of AA amyloidosis worldwide, differences also exist for AA amyloidosis complicating RA [22]. The reasons, however, for the marked geographic differences are unclear. The difference in the frequency of AA amy‐ loidosis among different races, and the fact that AA amyloidosis is not consistently related to the length and severity of chronic inflammation suggests that AA amyloidosis may be, at least in part, influenced by genetic factors [23-25].

## **4. Treatments of AA amyloidosis secondary to RA**

**Figure 3.** Kaplan-Meier survival curve after diagnosis of AA amyloidosis for patients with serum creatinine >2.5mg /dl (continuous line) and serum creatinine ≦2.5mg/dl (dotted line) (P=0.013, log-rank test) from Reference No. 9.

According to the information on the studies using radiolabelled human serum amyloid component P (SAP) as a specific quantitative *in vivo* scintigraphic tracer for monitoring of systemic AA amyloidosis [17], treatments those effectively suppress production of SAA halt the progressive accumulation of AA amyloid deposits and, in many cases, they are associat‐ ed with AA amyloid regression, improved organ function and survival [18, 19]. AA amyloid deposits are evidently turning over, their net size reflecting the balance of deposition and regression [20]. Therefore, AA amyloid deposits may regress at a low rate over a period of years and exist in a sate of dynamic turnover. The usual clinical impression of inexorable progression of AA amyloidosis actually reflects the progressive and usually incurable na‐ ture of the underlying primary condition, which is complicated by AA amyloidosis. Howev‐ er, new and aggressive approaches to therapy, such as cytotoxic anti-inflammatory drugs and biologic agents in chronic rheumatic inflammation, will lead to impressive AA amyloid regression and prolonged survival. Unfortunately these treatments do not always work and there are many difficult cases in those approaches are neither possible now nor likely to be‐ come feasible in future. In view of clinical significance of AA amyloidosis, there is an urgent need to facilitate studies into this complication. Early diagnosis and intervention are essen‐ tial for RA, however, few specific features are useful for diagnosis of RA and its diagnosis is often difficult in daily RA practice. Reduction of SAA load is currently the most rational ap‐ proach thereby arresting further deposition [21]. It is not exactly known why some patients develop a progressive AA amyloidosis while others do not, although latent deposits may be present. While there is startling variation in the frequency of AA amyloidosis worldwide, differences also exist for AA amyloidosis complicating RA [22]. The reasons, however, for

**3. Fundamental thoughts for therapies**

216 Amyloidosis

The principal aim in treating RA patients with AA amyloidosis is to switch off SAA produc‐ tion by controlling the RA inflammatory process. Anti-inflammatory treatment must be em‐ pirical but, as in all patients with AA amyloidosis, should be guided by frequent assessment of SAA concentrations in view of reported correlations between survival and this measure. Treatment of AA amyloidosis secondary to RA may involve the following strategies as out‐ lined in Table 1 [26].


1)AA:amyloid A, 2)RA:rheumatoid arthritis, 3)SAA:serum amyloid A protein, 4)eGFR: estimated glomerular filtration rate, 5)Ccr:creatinine clearance, 6)GI:gastrointestine, 7) T2T: treat RA to target, 8) HD:hemodialysis,9)MTX:methotrexate

**Table 1.** Clinical strategies in the management of AA1) amyloidosis secondary to RA2)

#### **4.1. Suppression of SAA production**

For AA amyloidosis in patients with RA, treatment has centered on using cytotoxic agents and is shifting to biologics recently. Although case reports and studies of small series of pa‐ tients showed that these agents can reverse nephrotic syndrome and even lead to complete resolution of proteinuria, anticytokine agents have recently been proposed as therapeutic options. Traditional management of AA amyloidosis has been to target RA disease to proc‐ ess behind the inflammation. Although there is no evidence that DMARDs have a specific effect on amyloidogenesis and AA amyloidosis in RA [27, 28], there have been encouraging reports evaluating alkylating agents as beneficial in clinical trials in RA patients with AA amyloidosis [29-33]. Treatments in AA amyloidosis secondary to RA including immunosup‐ pressants, biologics, and other supportive therapies will be discussed as follows.

#### *4.1.1. Immunosuppressants*

It is suggested that the use of immunosuppressive agents can improve prognosis [34], and CYC was superior to MTX in the management of RA patients with AA amyloidosis [9]. As regards MTX and CYC treatments, we observed differences of both serum C-reactive pro‐ tein (CRP) and Crea concentrations. That is, we subtracted the CRP- and/or Crea-value at initiation from the CRP- and/or Crea-value at endpoint of corresponding to each treatment. The each deducted value was dotted in Fig. 4. It was clear that more CYC treatments resided within minus area than MTX treatments. CRP improved 1.23±1.67 (mg/dl) in CYC treat‐ ments with statistical significance (*P*<0.001). We reported the possibility that CYC would be more effective predominantly in patients with SAA1.3/1.3 homozygosity than heterozygosi‐ ty, suggesting of CYC treatment-susceptible factor as SAA1.3/1.3 homozygosity [35]. Con‐ cerning immunosuppressants, whether specific therapies were warranted and were superior to previously reported regimens should be elucidated. The strategy of these treatments fo‐ cuses on tight control of underlying RA disease activity [28]. Requirements include diagno‐ sis of RA as early as possible and treatment with DMARDs, including MTX as the anchor drug. Achieving low disease activity via DMARDs in the early disease course has a strong positive outcome on disease progression. However, although MTX is the most common and effective drug for RA, management of patients with AA amyloidosis secondary to RA and renal involvement is too complex to limit the discussion on MTX.

**Figure 4.** Differences between CYC and MTX treatments for RA patients with AA amyloidosis. The detected value (placed in figures) was calculated by subtracting the starting value of CRP and/or serum creatinine from the endpoint

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

219

In RA treatment, tight control of RA is emphasized to obtain clinical remission or lower dis‐ ease activity; this control is possible through periodic evaluations of RA disease activity and aggressive pursuit of other more effective treatments [41-43]. Anti-proinflammatory cyto‐ kine therapy is expected to show efficacy against both systemic and local inflammation mediated by macrophage differentiation or activation in glomeruli, such as in renal AA

Infliximab (IFX) and ETN, both TNFα antagonists, can reduce serum SAA levels in RA pa‐ tients with AA amyloidosis, which improves rheumatoid inflammation, reduces swollen and tender joint counts, lowers or normalizes proteinuria, and ameliorates renal function [45-48]. Also, these agents showed amelioration in renal function for AA amyloidosis secon‐ dary to RA (Table 2) [10]. Despite the small number of series of patients with AA amyloido‐ sis secondary to RA who had ETN treatment, this drug did benefit both RA inflammation and AA amyloidosis, as measured via the surrogate markers, disease activity score (DAS)28 erythrocyte sedimentation rate (ESR), CRP, SAA, and proteinuria, in SAA1.3 allele-carrying RA patients (Fig. 5, Table 3). Further, Crea levels significantly improved in patients with mild RA disease and renal dysfunction (Table 4). This result suggests that the earlier the in‐ tervention with biologics, the better the outcome for patients. ETN alone may therefore be

value in each treatment from Reference No. 9.

amyloidosis secondary to RA [44].

efficacious, without MTX [49-53].

*4.1.2. Biologics*

For signal transduction, IL-6 binds to membrane-bound IL-6 receptor gp80 [36], and then the IL-6-gp80 dimer interacts with gp130. Formation of gp130-containing complexes leads to ac‐ tivation of Janus kinases (JAKs), which stimulates signal transducers and activators of tran‐ scription (STATs) [37]. Certain evidence suggests that STAT3 is the key transcription factor responsible for IL-6 activation of SAA gene transcription [38]. Therefore, the function of JAK inhibition in the IL-6 signaling pathway will be one target of RA treatments. Suppressing IL-6-mediated proinflammatory signaling pathways via JAK inhibitors may be a novel antiinflammatory therapeutic strategy for RA and AA amyloidosis. Another agent, tacrolimus, may inhibit T-cell function in pathogenesis of AA amyloidosis. The function of JAK inhibi‐ tion in the IL-6 signaling pathway will be one target of RA treatments [39, 40].

**Figure 4.** Differences between CYC and MTX treatments for RA patients with AA amyloidosis. The detected value (placed in figures) was calculated by subtracting the starting value of CRP and/or serum creatinine from the endpoint value in each treatment from Reference No. 9.

#### *4.1.2. Biologics*

**4.1. Suppression of SAA production**

218 Amyloidosis

*4.1.1. Immunosuppressants*

For AA amyloidosis in patients with RA, treatment has centered on using cytotoxic agents and is shifting to biologics recently. Although case reports and studies of small series of pa‐ tients showed that these agents can reverse nephrotic syndrome and even lead to complete resolution of proteinuria, anticytokine agents have recently been proposed as therapeutic options. Traditional management of AA amyloidosis has been to target RA disease to proc‐ ess behind the inflammation. Although there is no evidence that DMARDs have a specific effect on amyloidogenesis and AA amyloidosis in RA [27, 28], there have been encouraging reports evaluating alkylating agents as beneficial in clinical trials in RA patients with AA amyloidosis [29-33]. Treatments in AA amyloidosis secondary to RA including immunosup‐

It is suggested that the use of immunosuppressive agents can improve prognosis [34], and CYC was superior to MTX in the management of RA patients with AA amyloidosis [9]. As regards MTX and CYC treatments, we observed differences of both serum C-reactive pro‐ tein (CRP) and Crea concentrations. That is, we subtracted the CRP- and/or Crea-value at initiation from the CRP- and/or Crea-value at endpoint of corresponding to each treatment. The each deducted value was dotted in Fig. 4. It was clear that more CYC treatments resided within minus area than MTX treatments. CRP improved 1.23±1.67 (mg/dl) in CYC treat‐ ments with statistical significance (*P*<0.001). We reported the possibility that CYC would be more effective predominantly in patients with SAA1.3/1.3 homozygosity than heterozygosi‐ ty, suggesting of CYC treatment-susceptible factor as SAA1.3/1.3 homozygosity [35]. Con‐ cerning immunosuppressants, whether specific therapies were warranted and were superior to previously reported regimens should be elucidated. The strategy of these treatments fo‐ cuses on tight control of underlying RA disease activity [28]. Requirements include diagno‐ sis of RA as early as possible and treatment with DMARDs, including MTX as the anchor drug. Achieving low disease activity via DMARDs in the early disease course has a strong positive outcome on disease progression. However, although MTX is the most common and effective drug for RA, management of patients with AA amyloidosis secondary to RA and

For signal transduction, IL-6 binds to membrane-bound IL-6 receptor gp80 [36], and then the IL-6-gp80 dimer interacts with gp130. Formation of gp130-containing complexes leads to ac‐ tivation of Janus kinases (JAKs), which stimulates signal transducers and activators of tran‐ scription (STATs) [37]. Certain evidence suggests that STAT3 is the key transcription factor responsible for IL-6 activation of SAA gene transcription [38]. Therefore, the function of JAK inhibition in the IL-6 signaling pathway will be one target of RA treatments. Suppressing IL-6-mediated proinflammatory signaling pathways via JAK inhibitors may be a novel antiinflammatory therapeutic strategy for RA and AA amyloidosis. Another agent, tacrolimus, may inhibit T-cell function in pathogenesis of AA amyloidosis. The function of JAK inhibi‐

pressants, biologics, and other supportive therapies will be discussed as follows.

renal involvement is too complex to limit the discussion on MTX.

tion in the IL-6 signaling pathway will be one target of RA treatments [39, 40].

In RA treatment, tight control of RA is emphasized to obtain clinical remission or lower dis‐ ease activity; this control is possible through periodic evaluations of RA disease activity and aggressive pursuit of other more effective treatments [41-43]. Anti-proinflammatory cyto‐ kine therapy is expected to show efficacy against both systemic and local inflammation mediated by macrophage differentiation or activation in glomeruli, such as in renal AA amyloidosis secondary to RA [44].

Infliximab (IFX) and ETN, both TNFα antagonists, can reduce serum SAA levels in RA pa‐ tients with AA amyloidosis, which improves rheumatoid inflammation, reduces swollen and tender joint counts, lowers or normalizes proteinuria, and ameliorates renal function [45-48]. Also, these agents showed amelioration in renal function for AA amyloidosis secon‐ dary to RA (Table 2) [10]. Despite the small number of series of patients with AA amyloido‐ sis secondary to RA who had ETN treatment, this drug did benefit both RA inflammation and AA amyloidosis, as measured via the surrogate markers, disease activity score (DAS)28 erythrocyte sedimentation rate (ESR), CRP, SAA, and proteinuria, in SAA1.3 allele-carrying RA patients (Fig. 5, Table 3). Further, Crea levels significantly improved in patients with mild RA disease and renal dysfunction (Table 4). This result suggests that the earlier the in‐ tervention with biologics, the better the outcome for patients. ETN alone may therefore be efficacious, without MTX [49-53].

**Parameter Initial-visit Last-visit P-value**

DAS28-ESR 5.99±0.69 2.99±0.15 <0.01 CRP(mg/dl) 4.68±0.87 0.48±0.29 <0.01

SAA(μg/ml) 250±129 26±15 <0.01 Proteinuria(g/day) 2.24±0.81 0.57±0.41 <0.01 Serum creatinine(mg/dl) 2.54±1.38 2.50±2.21 0.896

**Table 3.** Surrogate markers between initial- and last-visit following treatment with etanercept

Parameter Baseline Clinical course (month)

 (n=14) 0 3 6 9 12 IL-6 (pg/ml) 11.2±12.9 107 40.4 24.8 7.6 1.7 TNFα (pg/ml) 1.04±0.36 2.2 1.4 1.3 1.1 1.1 IL-2 (U/ml) <0.8 <0.8 <0.8 <0.8 <0.8 <0.8 CD4+/CD8+ 1.30±0.58 2.04 1.63 1.54 1.72 1.77

Although Table 3 shows that the change in serum creatinine value was not statistically significant, when using a cutoff val‐ ue as less than 2.0 mg/dl at the initial-visit, it was demonstrated that the creatinine value improved significantly at the last-

Lymphocytes (%) 1.60±0.85 4.8 2.6 2.1 2.4 2.4 CD4+ T lymphocytes (%) 4.79±1.60 9 5.4 4.8 5.2 5.1

Tocilizumab (TCZ), an IL-6 receptor antagonist, can demonstrate excellent suppression of SAA levels and may have potential as the first candidate of the therapeutic agent for AA amyloidosis [7]. Circulating SAA normally reflects changes in CRP, and levels of both acute-phase reactants usually increase simultaneously, but some differences can occur. SAA and CRP seem to be part‐ ly influenced by different cytokines. IL-6-blocking therapy has shown promise in normalizing serum SAA levels in RA patients. Moreover, blocking IL-6 alone, but not IL-1 or TNFα, complete‐ ly prevented SAA mRNA expression in human hepatocytes during triple cytokine stimulation [54, 55]. Some reports with promising effect on AA amyloidosis secondary to RA may suggest a possibility of usefulness of this agent [56, 57]. Our case with end-stage renal disease due to AA amyloidosis secondary to RA showed validity of TCZ usage which is reaching to sustain normal SAA levels with successive treatment for 4 years (Fig. 6). In this case due to loss of joint function in advanced RA stage, in spite of lower and limited quality of life, both CRP and SAA are keeping

**Table 4.** Changes in the values of serum creatinine statifying by 2.0(mg/dl) at the commencement of etanercept

The values of DAS28=ESR, CRP, SAA, and proteinuria between the initial visit (before eta‐ nercept) and the last treatment (the index time) with etanercept. All improved with statisti‐ cal significance. In contrast, the serum creatinine did not change statistically. RA: rheumatoid arthritis, DAS: disease activity score, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, AA: amyloid A, SAA: serum amyloid A protein, \*serum levels. Quoted

DAS28-ESR 5.99±0.69 2.99±0.15 <0.01 CRP(mg/dl) 4.68±0.87 0.48±0.29 <0.01

SAA(μg/ml) 250±129 26±15 <0.01 Proteinuria(g/day) 2.24±0.81 0.57±0.41 <0.01 Serum creatinine(mg/dl) 2.54±1.38 2.50±2.21 0.896

**Less than 2.0(mg/dl) More than 2.0(mg/dl) (n=6) (n=8)**  Initial-visit Last-visit Initial-visit Last-visit (mg/dl) (mg/dl) (mg/dl) (mg/dl) 1.37±0.49 1.07±0.59 3.43±1.14 3.56±2.39 \* \*\*

Parameter Initial-visit Last-visit P-value

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

221

**RA inflammation**

**AA amyloidosis**

and modified from Reference No. 10.

CD4+CD25++FoxP3+ reg T

visit. Quoted and modified from Reference No. 10.

cells gated on

\*P=0.021,\*\*not significant

3

4

5

**RA inflammation**

**AA amyloidosis**

**Figure 5.** Chronological changes among surrogate markers following etanercept treatment. Ccr: creatinine clearance, CRP: C-reactive protein, DAS: disease activity score, n: number of patients treated with etanercept in the designated observation periods. CRP decreased dramatically by 20 weeks (P=0.018) and DAS28-ESR improved to low values signif‐ icantly following the treatment of etanercept. Although serum and calculated Ccr are coincided to be renal function markers, only serum albumin showed stastical significance between 0 and 96 weeks ( P=0.003), whereas the calculat‐ ed creatinine clearance fell gradually 0 and 96 weeks (P=0.776).


Quoted and modified from Reference No. 47. Data are represented as renal functions between the initial- and last-vist following biologics treatment. RA: rheumatoid arthritis, AA: amyloid A, Crea: levels of creatinine, IFX: infliximab, ETN: etanercept.

**Table 2.** Effect of TNF alpha blockers on renal AA amyloidosis secondary to RA.


The values of DAS28=ESR, CRP, SAA, and proteinuria between the initial visit (before eta‐ nercept) and the last treatment (the index time) with etanercept. All improved with statisti‐ cal significance. In contrast, the serum creatinine did not change statistically. RA: rheumatoid arthritis, DAS: disease activity score, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, AA: amyloid A, SAA: serum amyloid A protein, \*serum levels. Quoted and modified from Reference No. 10. Parameter Initial-visit Last-visit P-value **RA inflammation** DAS28-ESR 5.99±0.69 2.99±0.15 <0.01 CRP(mg/dl) 4.68±0.87 0.48±0.29 <0.01 **AA amyloidosis** SAA(μg/ml) 250±129 26±15 <0.01

**Table 3.** Surrogate markers between initial- and last-visit following treatment with etanercept Proteinuria(g/day) 2.24±0.81 0.57±0.41 <0.01 Serum creatinine(mg/dl) 2.54±1.38 2.50±2.21 0.896


#### \*P=0.021,\*\*not significant

CD4+CD25++FoxP3+ reg T

3

4

5

Intoroduction

ed creatinine clearance fell gradually 0 and 96 weeks (P=0.776).

**amyloidosis**

P=0.012

CRP

220 Amyloidosis

Calculated Ccr

Albumin

(g/dl)

DAS28‐(ESR)

etanercept.

(mg/dl)

5

P=0.018

4

3

1 2

0

> 0

(ml/min)

of etanercept Clinical course(week)

**Case/Age/Sex Duration (years) Biologics Proteinuria (g/day) Serum Crea**

1/70/F 18 1 IFX 2 6 93 130 3

2/59/F 13 4 ETN 1.2 0.2 398 425 12

3/59/F 13 4 ETN 1.2 0.72 229 246 7

4/37/M 22 2 IFX 3 0.9 134 145 17

**Table 2.** Effect of TNF alpha blockers on renal AA amyloidosis secondary to RA.

Quoted and modified from Reference No. 47. Data are represented as renal functions between the initial- and last-vist following biologics treatment. RA: rheumatoid arthritis, AA: amyloid A, Crea: levels of creatinine, IFX: infliximab, ETN:

P=0.003

P=0.776

> P=0.003

<sup>0</sup> <sup>20</sup> <sup>48</sup> <sup>72</sup> <sup>96</sup> <sup>120</sup> (n=14) (n=14) (n=13) (n=12) (n=6) (n=3)

**(months) RA AA**

**Figure 5.** Chronological changes among surrogate markers following etanercept treatment. Ccr: creatinine clearance, CRP: C-reactive protein, DAS: disease activity score, n: number of patients treated with etanercept in the designated observation periods. CRP decreased dramatically by 20 weeks (P=0.018) and DAS28-ESR improved to low values signif‐ icantly following the treatment of etanercept. Although serum and calculated Ccr are coincided to be renal function markers, only serum albumin showed stastical significance between 0 and 96 weeks ( P=0.003), whereas the calculat‐

P=0.029

**(mM/L**)

**Initial Last Initial Last**

**Observation Periods**

Parameter Baseline Clinical course (month) (n=14) 0 3 6 9 12 IL-6 (pg/ml) 11.2±12.9 107 40.4 24.8 7.6 1.7 TNFα (pg/ml) 1.04±0.36 2.2 1.4 1.3 1.1 1.1 Although Table 3 shows that the change in serum creatinine value was not statistically significant, when using a cutoff val‐ ue as less than 2.0 mg/dl at the initial-visit, it was demonstrated that the creatinine value improved significantly at the lastvisit. Quoted and modified from Reference No. 10.

IL-2 (U/ml) <0.8 <0.8 <0.8 <0.8 <0.8 <0.8 CD4+/CD8+ 1.30±0.58 2.04 1.63 1.54 1.72 1.77 **Table 4.** Changes in the values of serum creatinine statifying by 2.0(mg/dl) at the commencement of etanercept

cells gated on Lymphocytes (%) 1.60±0.85 4.8 2.6 2.1 2.4 2.4 CD4+ T lymphocytes (%) 4.79±1.60 9 5.4 4.8 5.2 5.1 Tocilizumab (TCZ), an IL-6 receptor antagonist, can demonstrate excellent suppression of SAA levels and may have potential as the first candidate of the therapeutic agent for AA amyloidosis [7]. Circulating SAA normally reflects changes in CRP, and levels of both acute-phase reactants usually increase simultaneously, but some differences can occur. SAA and CRP seem to be part‐ ly influenced by different cytokines. IL-6-blocking therapy has shown promise in normalizing serum SAA levels in RA patients. Moreover, blocking IL-6 alone, but not IL-1 or TNFα, complete‐ ly prevented SAA mRNA expression in human hepatocytes during triple cytokine stimulation [54, 55]. Some reports with promising effect on AA amyloidosis secondary to RA may suggest a possibility of usefulness of this agent [56, 57]. Our case with end-stage renal disease due to AA amyloidosis secondary to RA showed validity of TCZ usage which is reaching to sustain normal SAA levels with successive treatment for 4 years (Fig. 6). In this case due to loss of joint function in advanced RA stage, in spite of lower and limited quality of life, both CRP and SAA are keeping within normal limits, those may lead to decreasing proteinuria. It is needed to clarify the dissoci‐ ation between inflammatory rheumatoid activity and destructed articular function under cur‐ rent RA therapeutic strategies using biologics like "disconnect" phenomenon [58].

tacrolims inhibited AA amyloid fibril deposits in a dose-dependent manner without influ‐ encing SAA concentrations. Also, the locality of CD4+ T lymphocytes in the spleen was par‐ tially identical to AA amyloid fibril deposits histologically, suggesting the role of T

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

223

0 3 6 9 12

**Figure 7.** Effect of abatacept on AA amyloidosis secondary to RA. Inflammatory markers, CRP and SAA, decreased gradually, and renal dysfunction ameliorated with the treatment of abatacept. ABT: abatacept, eGFR: estimated glo‐ merular filtration rate, SAA: serum amyloid A protein, CRP: C-reactive protein, mHAQ: modified health assessment

**Figure 8.** Histological changes before (A) the treatment with abatacept and after (B) one year in the disease course. Amorphous deposits were detected in the specimen from upper gastrointestinal biopsy with Congo Red staining (A).

**Clinical course (month) Introduction of ABT** 

questionnaire, DAS: disease activity score, ESR: erythrocyte sedimentation rate.

Those disappeared with abatacept treatment after one year (B).

lymphocytes in the pathogenesis of AA amyloidosis [39].

0 50 100

0 200 300

> 0 4 8

5 4 6

2

3

100 SAA(μg/ml)

CRP(mg/dl)

mHAQ ( )

DAS28-ESR ( )

eGFR

(ml/min/1.73m2

)

**Fig. 6 Figure 6.** Effect of tocilizumab on AA amyloidosis secondary to RA. DAS28-ESR showed gradually regressed with the association of CRP, however, levels of serum creatinine increased leading to end-stage renal disease. TCZ had an effect on both proteinuria and rheumatoid inflammation, nevertheless, this case showed late dissociation between rheuma‐ toid inflammation and joint functional activity. TCZ: tocilizumab, ETN: etanercept, PSL: prednisolone, Crea: serum crea‐ tinine, CRP: C-reactive protein.

T lymphocyte costimulation is a key point in the regulation of immune tolerance, immune response, and autoimmunity. T lymphocyte activation does not take place upon the simple engagement of T cell receptor; a second signal is needed to fully stimulate T lymphocytes. There are a variety of molecules that can act as costimulators, and among these cluster of differentiation (CD)28/CD80 signaling plays a crucial role in modulating T lymphocyte re‐ sponse. Cytotoxic T lymphocyte antigen-4 (CTLA4) is a physiologic antagonist of CD28, and abatacept (ABT), a synthetic analogue of CTLA4, has recently been approved to treat RA. A 70-year-old Japanese woman had been suffering from RA for 28 years with Steinbrocker's Stage IV and functional Class 2. She was biopsy-confirmed as AA amyloidosis carried with SAA1.3/1.5 allele genotype. ABT was initiated from January 2011 and her clinical course was shown in Fig. 7. The histopathological findings from upper gastrointestinal (GI) biopsy be‐ tween before and after 1 year from the commencement of ABT revealed a disappearance of AA amyloid fibril deposition (Fig. 8-A, -B). The changes in markers on cytokines and lym‐ phocyte expression might suggest an effect of ABT from the points of immunological aspect in the case (Table 5). These results would show effectiveness of this agent on both RA and AA amyloidosis, with being required further elucidations. In experimental mouse models of AA amyloidosis, blocking T lymphocytes function by the calcinulin inhibitor showed that tacrolims inhibited AA amyloid fibril deposits in a dose-dependent manner without influ‐ encing SAA concentrations. Also, the locality of CD4+ T lymphocytes in the spleen was par‐ tially identical to AA amyloid fibril deposits histologically, suggesting the role of T lymphocytes in the pathogenesis of AA amyloidosis [39].

within normal limits, those may lead to decreasing proteinuria. It is needed to clarify the dissoci‐ ation between inflammatory rheumatoid activity and destructed articular function under cur‐

May,2008 Sep,2008 Aug,2009 Aug,2010 Mar,2011 Aug,2011 Jul,2012

**Fig. 6 Figure 6.** Effect of tocilizumab on AA amyloidosis secondary to RA. DAS28-ESR showed gradually regressed with the association of CRP, however, levels of serum creatinine increased leading to end-stage renal disease. TCZ had an effect on both proteinuria and rheumatoid inflammation, nevertheless, this case showed late dissociation between rheuma‐ toid inflammation and joint functional activity. TCZ: tocilizumab, ETN: etanercept, PSL: prednisolone, Crea: serum crea‐

T lymphocyte costimulation is a key point in the regulation of immune tolerance, immune response, and autoimmunity. T lymphocyte activation does not take place upon the simple engagement of T cell receptor; a second signal is needed to fully stimulate T lymphocytes. There are a variety of molecules that can act as costimulators, and among these cluster of differentiation (CD)28/CD80 signaling plays a crucial role in modulating T lymphocyte re‐ sponse. Cytotoxic T lymphocyte antigen-4 (CTLA4) is a physiologic antagonist of CD28, and abatacept (ABT), a synthetic analogue of CTLA4, has recently been approved to treat RA. A 70-year-old Japanese woman had been suffering from RA for 28 years with Steinbrocker's Stage IV and functional Class 2. She was biopsy-confirmed as AA amyloidosis carried with SAA1.3/1.5 allele genotype. ABT was initiated from January 2011 and her clinical course was shown in Fig. 7. The histopathological findings from upper gastrointestinal (GI) biopsy be‐ tween before and after 1 year from the commencement of ABT revealed a disappearance of AA amyloid fibril deposition (Fig. 8-A, -B). The changes in markers on cytokines and lym‐ phocyte expression might suggest an effect of ABT from the points of immunological aspect in the case (Table 5). These results would show effectiveness of this agent on both RA and AA amyloidosis, with being required further elucidations. In experimental mouse models of AA amyloidosis, blocking T lymphocytes function by the calcinulin inhibitor showed that

**Decreasing proteinuria** 

**Steinbrocker's classification Stage IV Class 2** 

**Late dissociation** 

rent RA therapeutic strategies using biologics like "disconnect" phenomenon [58].

ETN 25mg/week TCZ 280mg/month 7.5 10

PSL 20mg/day <sup>15</sup>

CRP(mg/dl)

222 Amyloidosis

Crea(mg/dl) 0

DAS28-ESR

3 2 1

> 6 3 0

tinine, CRP: C-reactive protein.

**Figure 7.** Effect of abatacept on AA amyloidosis secondary to RA. Inflammatory markers, CRP and SAA, decreased gradually, and renal dysfunction ameliorated with the treatment of abatacept. ABT: abatacept, eGFR: estimated glo‐ merular filtration rate, SAA: serum amyloid A protein, CRP: C-reactive protein, mHAQ: modified health assessment questionnaire, DAS: disease activity score, ESR: erythrocyte sedimentation rate.

**Figure 8.** Histological changes before (A) the treatment with abatacept and after (B) one year in the disease course. Amorphous deposits were detected in the specimen from upper gastrointestinal biopsy with Congo Red staining (A). Those disappeared with abatacept treatment after one year (B).


dose prednisolone inclusion in a MTX-based tight control strategy for early RA would be

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

225

Eprodisate, a small sulfonated molecule with structural similarity to heparan sulfate, which can cause regression of amyloidosis by destabilizing the glycoasaminoglycan backbone of amyloid deposits, delayed progression of renal disease associated with AA amyloidosis. In a trial for AA amyloidosis, eprodisate had a beneficial effect on the rate of deterioration of re‐ nal function but no effect on urinary protein excretion [68]. Because eprodisate did not affect SAA levels and preserved kidney function but had no effect on proteinuria, the interesting possibility that it is the precursors of mature amyloid fibrils are responsible for proteinuria in amyloidosis would raise. In the light of higher effects of biologics on AA amyloidosis sec‐ ondary to RA, the usefulness of eprodisate seems to be inferior to that of biologic under the

The normal plasma protein SAP binds to all types of amyloid fibrils and contributes to amy‐ loidosis pathogenesis [69]. A pyrrolidine carboxylic acid derivative, which is a competitive inhibitor of SAP binding to amyloid fibrils, can intervere in this process and affect SAP lev‐ els. This compound cross-linked and dimerized SAP molecules, which led to extremely rap‐ id clearance by the liver, and thus produced marked depletion of circulating human SAP. Therefore, this drug action removed SAP from human amyloid deposits in tissues and may

Another compound, dimethyl sulfoxide (DMSO), is a hydrogen-bond disrupter, cell-differ‐ entiating agent, hydroxyl radical scavenger, cryoprotectant, and solubilizing agent that is used as a compound for preparation of samples for electron microscopy, as an intracellular low-density lipoprotein-derived cholesterol-mobilizing antidote to extravasation of vesicant anticancer agents, and as a topical analgesic. A notable DMSO side effect is garlic-like breath odor and taste in the mouth because of pulmonary excretion of a small amount of DMSO as dimethyl sulfide [71]. Oral DMSO was effective against AA amyloidosis, especially GI in‐ volvement and early renal dysfunction [72], but using it would not likely be feasible in cur‐

The predominant feature of AA amyloidosis is proteinuria with or without renal failure. If con‐ servative treatment of renal failure is not sufficient, renal replacement therapy including renal transplantation, continuous ambulatory peritoneal dialysis, or hemodialysis (HD) should be considered. Even in RA patients with AA amyloidosis who undergo HD, anti-TNFα blockers can demonstrate efficacy [11, 73]. HD reportedly had no effect on plasma ETN concentration, and ETN pharmacokinetics in patients undergoing HD for chronic renal failure were similar to

effective, thus could be improved for AA amyloidosis secondary to RA [67].

**4.2. Inhibition of AA amyloid fibril deposits**

**4.3. Removal of deposited AA amyloid fibrils**

have a favorable effect on amyloidosis [70].

biologics era.

rent clinical practice.

**4.4. Treatment of organ failure**

Baseline values were determined and expressed by mean ± S.D. of 14 RA patients, matched by disease duration and disease severity to this case. IL-6: interleukin-6, TNFa: tumor necrosis factor alpha, IL-2: interleukin -2, reg T: regulatory T lymphocyte.

**Table 5.** Changes in cytokines and regulatory T lymphocyte expression after abatacept treatment

Rituximab (RTX), an anti-CD20 monoclonal antibody, was efficacious for patients with se‐ vere active RA who have exhibited an inadequate response to one or more TNFα inhibitors [59]. Also, this agent was administered alone in two RA patients and in combination with MTX in other two RA cases with histologic confirmation of AA amyloidosis. The four pa‐ tients showed a significant clinical improvement of the articular symptoms and marked re‐ duction of the acute phase-reactants. Renal function remained stable in all patients and proteinuria improved in two, worsened in one, and remained stable in the fourth with few adverse effects [60].

Clinical trials are warranted to assess the long-term safety and efficacy of biological treat‐ ments and their impacts on the survival of RA patients with AA amyloidosis.

#### *4.1.3. Corticosteroids*

The effect of corticosteroid treatment on AA amyloidosis is still controversial. Corticoste‐ roids are capable of reducing the magnitude of the acute phase reaction including the syn‐ thesis of CRP and SAA. In human hepatocyte cultures a stimulating effect of corticosteroids was seen on SAA but not on CRP production [61, 62]. Although corticosteroid therapy sup‐ presses both CRP and SAA levels in longitudinal studies of patients with RA, the effect is somewhat more pronounced for CRP than for SAA [63]. Monitoring of SAA instead of CRP levels would be advisable particularly if corticosteroids are being used. It seems reasonable to treat patients with AA amyloidosis secondary to RA using cytostatic drugs either alone or in combination with prednisolone [64-66]. As the effect of cytostatics may take weeks or months to appear, it is recommended to give steroids additionally in order to ensure an im‐ mediate reduction of the acute phase response and in particular the synthesis of SAA. Lowdose prednisolone inclusion in a MTX-based tight control strategy for early RA would be effective, thus could be improved for AA amyloidosis secondary to RA [67].

#### **4.2. Inhibition of AA amyloid fibril deposits**

**Parameter Baseline Clinical course (month)**

CD4+CD25++FoxP3+ reg T cells

gated on

224 Amyloidosis

T lymphocyte.

adverse effects [60].

*4.1.3. Corticosteroids*

IL-6 (pg/ml) 11.2±12.9 107 40.4 24.8 7.6 1.7 TNFα (pg/ml) 1.04±0.36 2.2 1.4 1.3 1.1 1.1 IL-2 (U/ml) <0.8 <0.8 <0.8 <0.8 <0.8 <0.8 CD4+/CD8+ 1.30±0.58 2.04 1.63 1.54 1.72 1.77

Lymphocytes (%) 1.60±0.85 4.8 2.6 2.1 2.4 2.4 CD4+ T lymphocytes (%) 4.79±1.60 9 5.4 4.8 5.2 5.1

**Table 5.** Changes in cytokines and regulatory T lymphocyte expression after abatacept treatment

ments and their impacts on the survival of RA patients with AA amyloidosis.

Baseline values were determined and expressed by mean ± S.D. of 14 RA patients, matched by disease duration and disease severity to this case. IL-6: interleukin-6, TNFa: tumor necrosis factor alpha, IL-2: interleukin -2, reg T: regulatory

Rituximab (RTX), an anti-CD20 monoclonal antibody, was efficacious for patients with se‐ vere active RA who have exhibited an inadequate response to one or more TNFα inhibitors [59]. Also, this agent was administered alone in two RA patients and in combination with MTX in other two RA cases with histologic confirmation of AA amyloidosis. The four pa‐ tients showed a significant clinical improvement of the articular symptoms and marked re‐ duction of the acute phase-reactants. Renal function remained stable in all patients and proteinuria improved in two, worsened in one, and remained stable in the fourth with few

Clinical trials are warranted to assess the long-term safety and efficacy of biological treat‐

The effect of corticosteroid treatment on AA amyloidosis is still controversial. Corticoste‐ roids are capable of reducing the magnitude of the acute phase reaction including the syn‐ thesis of CRP and SAA. In human hepatocyte cultures a stimulating effect of corticosteroids was seen on SAA but not on CRP production [61, 62]. Although corticosteroid therapy sup‐ presses both CRP and SAA levels in longitudinal studies of patients with RA, the effect is somewhat more pronounced for CRP than for SAA [63]. Monitoring of SAA instead of CRP levels would be advisable particularly if corticosteroids are being used. It seems reasonable to treat patients with AA amyloidosis secondary to RA using cytostatic drugs either alone or in combination with prednisolone [64-66]. As the effect of cytostatics may take weeks or months to appear, it is recommended to give steroids additionally in order to ensure an im‐ mediate reduction of the acute phase response and in particular the synthesis of SAA. Low-

(n=14) 0 3 6 9 12

Eprodisate, a small sulfonated molecule with structural similarity to heparan sulfate, which can cause regression of amyloidosis by destabilizing the glycoasaminoglycan backbone of amyloid deposits, delayed progression of renal disease associated with AA amyloidosis. In a trial for AA amyloidosis, eprodisate had a beneficial effect on the rate of deterioration of re‐ nal function but no effect on urinary protein excretion [68]. Because eprodisate did not affect SAA levels and preserved kidney function but had no effect on proteinuria, the interesting possibility that it is the precursors of mature amyloid fibrils are responsible for proteinuria in amyloidosis would raise. In the light of higher effects of biologics on AA amyloidosis sec‐ ondary to RA, the usefulness of eprodisate seems to be inferior to that of biologic under the biologics era.

#### **4.3. Removal of deposited AA amyloid fibrils**

The normal plasma protein SAP binds to all types of amyloid fibrils and contributes to amy‐ loidosis pathogenesis [69]. A pyrrolidine carboxylic acid derivative, which is a competitive inhibitor of SAP binding to amyloid fibrils, can intervere in this process and affect SAP lev‐ els. This compound cross-linked and dimerized SAP molecules, which led to extremely rap‐ id clearance by the liver, and thus produced marked depletion of circulating human SAP. Therefore, this drug action removed SAP from human amyloid deposits in tissues and may have a favorable effect on amyloidosis [70].

Another compound, dimethyl sulfoxide (DMSO), is a hydrogen-bond disrupter, cell-differ‐ entiating agent, hydroxyl radical scavenger, cryoprotectant, and solubilizing agent that is used as a compound for preparation of samples for electron microscopy, as an intracellular low-density lipoprotein-derived cholesterol-mobilizing antidote to extravasation of vesicant anticancer agents, and as a topical analgesic. A notable DMSO side effect is garlic-like breath odor and taste in the mouth because of pulmonary excretion of a small amount of DMSO as dimethyl sulfide [71]. Oral DMSO was effective against AA amyloidosis, especially GI in‐ volvement and early renal dysfunction [72], but using it would not likely be feasible in cur‐ rent clinical practice.

#### **4.4. Treatment of organ failure**

The predominant feature of AA amyloidosis is proteinuria with or without renal failure. If con‐ servative treatment of renal failure is not sufficient, renal replacement therapy including renal transplantation, continuous ambulatory peritoneal dialysis, or hemodialysis (HD) should be considered. Even in RA patients with AA amyloidosis who undergo HD, anti-TNFα blockers can demonstrate efficacy [11, 73]. HD reportedly had no effect on plasma ETN concentration, and ETN pharmacokinetics in patients undergoing HD for chronic renal failure were similar to those with normal renal function [74]. Administration of ETN to HD patients would therefore appear reasonable. Renal replacement therapy is discussed in Table 6.

**5.1. Patients and methods**

AL amyloidosis.

cember 2004.

This retrospective cohort study compared effectiveness of CYC and ETN for RA patients with AA amyloidosis who were homozygous for the SAA1.3 allele or other polymorphisms. Sixty-two RA patients received CYC and 24 did ETN; all had biopsy-confirmed AA amyloi‐ dosis. The presence of AA amyloid deposits was confirmed histologically via positive Con‐ go Red staining, potassium permanganate susceptibility, and green birefringence seen by polarization microscopy after Congo Red staining, as well as immunohistochemical analysis using anti-AA antibody and anti-immunoglobulin light-chain (AL) antibody to differentiate

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

227

Patients with RA had been treated with non-steroidal anti-inflammatory drugs (NSAIDs), prednisolone, DMARDs, and immunosuppressive agents but were often refractory to these agents. Although CYC had been unallowable medico-legally in Japanese governmental health insurance system and we were able to use CYC for RA treatment from August 2010 in Japan, we finally used CYC and investigated its efficacy for enrolled patients until De‐

Age, sex, and duration of RA and AA amyloidosis were recorded, as were changes in labo‐ ratory indices and clinical evaluations of disease activity included CRP, SAA, ESR, rheuma‐ toid factor (RF), serum Alb, Crea, 24-hour proteinuria, and eGFR. Use of DMARDs, immunosuppressants, or PSL from the time of RA onset to the index time was noted. We chose CRP as an indicator of rheumatoid inflammation and Alb as an indicator of severity of AA amyloidosis [76]. Because renal dysfunction is the most common symptom in AA amy‐ loidosis secondary to RA, we selected Crea and eGFR to assess treatment effectiveness. We calculated eGFRs via the nomogram for modification of diet reported in a Japanese renal disease study (index 0.741) using Crea measured by using an enzymatic method [77]. We al‐ so obtained information on drugs including DMARDs, NSAIDs, angiotensin-converting en‐ zyme inhibitors, and angiotensin II receptor blockers. We recorded clinical symptoms and arthritis activity for each time point. We carefully checked adverse effects of immunosup‐ pressants, *e.g*. infection risks, myelosuppression, haemorrhagic cystitis, and carcinogenesis. We monitored biomarker levels and compared initial (before treatment) and last (after treat‐ ment) values. We used statistical analysis to assess effects of the SAA1.3 allele on therapies. We determined the onset of RA by reviewing of charts after AA amyloidosis diagnosis had been confirmed. Clinical symptoms at presentation were the main reason for physicians to obtain tissue biopsies to demonstrate AA amyloid deposits. We estimated survival curves via the Kaplan-Maier technique; we analyzed statistical differences between two curves by the log-rank test. We used Cox proportional hazards models to assess effects of treatments on eGFR and 24-hour proteinuria, with risk of death as the endpoint. We used two-way re‐ peated-measures analysis of ANOVA to simultaneously estimate effects of SAA1.3 or treat‐ ments on individual changes in biomarkers. In the model, individual change was defined as within-subjects factors; categorical groups, i.e. polymorphisms of the SAA1.3 allele and treatments, were defined as between-subjects factors. To determine the factor affecting indi‐ vidual change, a combined factor (within and between) was defined as interaction. We eval‐ uated significant effects of these factors via ANOVA. We determined significant interaction

#### **Renal transplantation**

Immonen K, et al: J Rheumatol 2008; 35: 1334-8

30 cases in 332 RA patients with AA amyloidosis

Median survival: 2.11 years

#### **Peritoneal dialysis/Hemodialysis (HD)**

Bergesio F, et al: Nephrol Dial Transplant 2008; 23: 941-51

Prognosis: 17 months

Kuroda T, et al: Reference No. 73

96.9 person-year followup: 42 patients died

50% survival from the initiation of HD: 251 days

Ccr was superior to Crea, Advisable planned initiation of HD

Nakamura T, et al: Reference No. 11

51.8 months Dialysis with ETN 27.8 months Use

Amelioration of DAS28-ESR, CRP, mHAQ, and ESR

RA: rheumatoid arthritis, AA: amyloid A, HD: hemodialysis, Ccr: creatinine clearance, Crea: serum levels of creatinine, ETN: etanercept, DAS: disease activity score, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, mHAQ: modified health assessment questionnaire.

**Table 6.** Renal replacement therapy in AA amyloidosis secondary to RA

#### **5. Comparison of effectiveness between biologic and alkylating agent**

We previously showed that the genetic predisposition allele SAA1.3 was not only a univari‐ ate predictor of survival but also a risk factor for association of AA amyloidosis with RA in Japanese patients [9], and in view of our earlier reports on the efficacy of ETN [10, 48] and CYC [35, 64] given alone for AA amyloidosis secondary to RA, we compared the effective‐ ness of ETN and CYC, and we assessed biomarkers and analyzed the effect of SAA1.3 allele on these treatments [75].

#### **5.1. Patients and methods**

those with normal renal function [74]. Administration of ETN to HD patients would therefore

appear reasonable. Renal replacement therapy is discussed in Table 6.

Immonen K, et al: J Rheumatol 2008; 35: 1334-8

Median survival: 2.11 years

Prognosis: 17 months

Kuroda T, et al: Reference No. 73

Nakamura T, et al: Reference No. 11

modified health assessment questionnaire.

on these treatments [75].

**Peritoneal dialysis/Hemodialysis (HD)**

30 cases in 332 RA patients with AA amyloidosis

Bergesio F, et al: Nephrol Dial Transplant 2008; 23: 941-51

96.9 person-year followup: 42 patients died

50% survival from the initiation of HD: 251 days

51.8 months Dialysis with ETN 27.8 months Use

Amelioration of DAS28-ESR, CRP, mHAQ, and ESR

**Table 6.** Renal replacement therapy in AA amyloidosis secondary to RA

Ccr was superior to Crea, Advisable planned initiation of HD

RA: rheumatoid arthritis, AA: amyloid A, HD: hemodialysis, Ccr: creatinine clearance, Crea: serum levels of creatinine, ETN: etanercept, DAS: disease activity score, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, mHAQ:

**5. Comparison of effectiveness between biologic and alkylating agent**

We previously showed that the genetic predisposition allele SAA1.3 was not only a univari‐ ate predictor of survival but also a risk factor for association of AA amyloidosis with RA in Japanese patients [9], and in view of our earlier reports on the efficacy of ETN [10, 48] and CYC [35, 64] given alone for AA amyloidosis secondary to RA, we compared the effective‐ ness of ETN and CYC, and we assessed biomarkers and analyzed the effect of SAA1.3 allele

**Renal transplantation**

226 Amyloidosis

This retrospective cohort study compared effectiveness of CYC and ETN for RA patients with AA amyloidosis who were homozygous for the SAA1.3 allele or other polymorphisms. Sixty-two RA patients received CYC and 24 did ETN; all had biopsy-confirmed AA amyloi‐ dosis. The presence of AA amyloid deposits was confirmed histologically via positive Con‐ go Red staining, potassium permanganate susceptibility, and green birefringence seen by polarization microscopy after Congo Red staining, as well as immunohistochemical analysis using anti-AA antibody and anti-immunoglobulin light-chain (AL) antibody to differentiate AL amyloidosis.

Patients with RA had been treated with non-steroidal anti-inflammatory drugs (NSAIDs), prednisolone, DMARDs, and immunosuppressive agents but were often refractory to these agents. Although CYC had been unallowable medico-legally in Japanese governmental health insurance system and we were able to use CYC for RA treatment from August 2010 in Japan, we finally used CYC and investigated its efficacy for enrolled patients until De‐ cember 2004.

Age, sex, and duration of RA and AA amyloidosis were recorded, as were changes in labo‐ ratory indices and clinical evaluations of disease activity included CRP, SAA, ESR, rheuma‐ toid factor (RF), serum Alb, Crea, 24-hour proteinuria, and eGFR. Use of DMARDs, immunosuppressants, or PSL from the time of RA onset to the index time was noted. We chose CRP as an indicator of rheumatoid inflammation and Alb as an indicator of severity of AA amyloidosis [76]. Because renal dysfunction is the most common symptom in AA amy‐ loidosis secondary to RA, we selected Crea and eGFR to assess treatment effectiveness. We calculated eGFRs via the nomogram for modification of diet reported in a Japanese renal disease study (index 0.741) using Crea measured by using an enzymatic method [77]. We al‐ so obtained information on drugs including DMARDs, NSAIDs, angiotensin-converting en‐ zyme inhibitors, and angiotensin II receptor blockers. We recorded clinical symptoms and arthritis activity for each time point. We carefully checked adverse effects of immunosup‐ pressants, *e.g*. infection risks, myelosuppression, haemorrhagic cystitis, and carcinogenesis.

We monitored biomarker levels and compared initial (before treatment) and last (after treat‐ ment) values. We used statistical analysis to assess effects of the SAA1.3 allele on therapies. We determined the onset of RA by reviewing of charts after AA amyloidosis diagnosis had been confirmed. Clinical symptoms at presentation were the main reason for physicians to obtain tissue biopsies to demonstrate AA amyloid deposits. We estimated survival curves via the Kaplan-Maier technique; we analyzed statistical differences between two curves by the log-rank test. We used Cox proportional hazards models to assess effects of treatments on eGFR and 24-hour proteinuria, with risk of death as the endpoint. We used two-way re‐ peated-measures analysis of ANOVA to simultaneously estimate effects of SAA1.3 or treat‐ ments on individual changes in biomarkers. In the model, individual change was defined as within-subjects factors; categorical groups, i.e. polymorphisms of the SAA1.3 allele and treatments, were defined as between-subjects factors. To determine the factor affecting indi‐ vidual change, a combined factor (within and between) was defined as interaction. We eval‐ uated significant effects of these factors via ANOVA. We determined significant interaction of effects of groups (SAA1.3 or treatments) on changes in individual markers. Findings were statistically significant at *P*<0.05. We used SPSS Statistics 17.0, Base and Advanced (SPSS Inc, Chicago, IL, USA) for statistical analyses.

**CYC (n=62)2) ETN (n=24)3) P-value4)**

http://dx.doi.org/10.5772/53801

229

**I.** Sex, Male/Female, n 12/50 4/20 1.000

Stage II,III,IV, n 5/18/39 3/7/14 Class 2/3/4, n 38/18/6 14/7/3 **II** MTX therapy (yes/no), n 31/31 15/9 0.297

**III** CRP (mg/dl, mean) 3.99 (1.72) 3.89 (1.97) 0.820

**IV** Cause of death, n (%) n=26 (41.9) n=8 (33.3) 0.464 Infectious pneumonia 6 3

Interstitial pneumonia 4 1

Congestive heart failure 7 2 Renal failure 1 1 Malignancy 1

1) Baseline data were at the initiation of each treatment. All patients, except those who died, were followed from Janu‐ ary 1995 to December 2010. Last observations were made in December 2004 for the CYC group and December 2010 for the ETN group. Vales are represented by mean (S.D.) unless otherwise noted. Causes of death of patients who died during the study, and these causes were most closely related to their death. 2)CYC was given until December, 2004. Thirty-six alive [8 males, 28 females; mean (S.D.) age = 65.7 (10.8) years] and 26 dead [3 males, 23 females; mean (S.D.) age = 71.9 (8.5) years]. CYC was treated according to the level of 24-h Ccr: Ccr≧80 (ml/min): 100 (mg/day), 60≦Ccr < 80 (ml/min): 75 (mg/day), 40≦Ccr < 60 (ml/min): 40 (mg/day), 10≦Ccr < 20 (ml/min): 25 (mg/day), Ccr < 10 (ml/ min): 20 (mg /day). 3)ETN was until December, 2010. Sixteen alive [3 males, 13 females; mean (S.D.) age = 64.2 (8.5) years] and 8 dead [1 male, 7 females; mean (S.D.) age = 66.0 (7.8) years]. 4)Student's-*t* analysis was performed to com‐ pare CYC and ETN, with P < 0.05 indicating a significant result. 5)Stenbrocher'scalassification according to JAMA 1949;

Sepsis 2 GI ulcer/bleeding 3

Myocardial infarction 2

Unknown 1

140: 659-62.Quoted from Reference No. 75.

**Table 7.** Clinical characteristics and laboratory findings of patients1)

Months since diagnosis of AA

Steinbrocker's classification5)

SAA1.3 allele, Homozygout/Others, n 22/40 16/8 0.015 Months since RA onset (mean) 176.0 (111.0) 195.3 (88.3) 0.447

amyloidosis (mean) 22.9(41.7) 67.5 (42.5) <0.001 Months of treatment (mean) 38.0 (27.4) 34.0 (23.1) 0.526

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

PSL dosage (mg/day, mean) 9.91(5.88) 7.97 (4.96) 0.516

SAA (μg/ml, mean) 294.8 (166.0) 327.0 (223.4) 0.467 eGFR (ml/min/1.73 ㎡, mean) 29.2 (23.9) 31.2 (20.6) 0.714 Crea(mg/dl, mean) 2.04 (0.95) 2.23 (1.27) 0.465 24-Hour urinary protein (g, mean) 1.53 (0.84) 2.09 (1.27) 0.020 Serum Alb (g/dl, mean) 2.92 (0.32) 3.04 (0.68) 0.128 RF (U/ml, mean) 237.8 (262.1) 200.8 (154.3) 0.519

#### **5.2. Results**

Table 7 provides patients' clinical characteristics and laboratory findings. Despite treatments being administered during different periods, clinical and laboratory findings of both groups were quite similar at the start of each treatment, except for the SAA1.3 genotype and dura‐ tion AA amyloidosis since diagnosis (*P*=0.015 and *P*<0.001, respectively). With regard to bio‐ markers indicating renal dysfunction, ETN had worse kidney damage than did CYC. During the study, patients died in each treatment group at the almost same rate. In the CYC group, congestive heart failure and infectious pneumonia occurred frequently. Patients giv‐ en ETN had a lower rate of congestive heart failure as cause of death, suggesting of the pos‐ sibility of an inhibitory effect on progressive heart failure.

Years since RA onset and years since diagnosis of AA amyloidosis were significantly differ‐ ent for SAA1.3 homozygosity *vs* other genotypes (15.6±7.8 *vs* 21.4±9.9, *P*=0.046, and 7.44±4.9 *vs* 9.7±4.5, *P*=0.016, respectively). Comparison of CRP, Alb, eGFR, and Crea for both groups at initial and final observations, disregarding SAA1.3 allele polymorphisms, showed that ETN reduced serum CRP levels and increased serum Alb levels more than did CYC (ETN *vs* CYC: CRP: from 4.7±0.8 to 0.5±0.3 mg/dl *vs* from 4.0±1.6 to 2.8±1.2 mg/dl, *P*<0.01; Alb: from 2.6±0.4 to 3.5±0.4 g/dl *vs* from 2.8±0.3 to 2.8±0.5 g/dl, *P*<0.01, respectively). Thus, ETN signifi‐ cantly improved serum CRP and Alb levels and was clearly more effective than CYC. CRP and Alb interactions with polymorphism (homozygous for SAA1.3 or other polymorphisms) showed no significance (*P*=0.777 and *P*=0.715, respectively), but CRP and Alb interactions with treatment (ETN or CYC) demonstrated significant results (both *P*<0.01). Within-subject analysis showed that treatments improved eGFR: ETN: from 21.8±18.9 to 24.9±18.7 ml/min/ 1.73m2 *vs* CYC: from 29.3±12.7 to 18.6±9.3 ml/min/1.73m2 , *P*=0.035, with ETN's effect on eGFR being significant (*P*=0.032). ETN increased eGFR, thus improving the decreased renal function caused by AA amyloidosis, more than did CYC (Fig. 9A), but this effect was not related to SAA1.3 allele polymorphisms (Fig. 9B). Neither treatment affected Crea levels. SAA1.3 allele did not affect treatment in both groups of patients, as evidenced by interac‐ tions of SAA1.3 allele with CRP, Alb, eGFR, and Crea (*P*=0.777, *P*=0.715, *P*=0.465, and *P*=0.228, respectively).

Because ETN was more effective than CYC, according to CRP, Alb, and eGFR measures, we calculated the hazard ratio between ETN and CYC as a survival parameter. According to Cox proportional hazards survival analysis, ETN significantly improved survival (*P*=0.025). Also, the Kaplan-Meier curves showed a significant difference between ETN and CYC (Fig. 10). The hazard ratio for ETN evidenced significant results for the risk of death endpoint (eGFR: *P*=0.024 and 24-hour proteinuria: *P*=0.025, respectively) but CYC did not (Table 8).


1) Baseline data were at the initiation of each treatment. All patients, except those who died, were followed from Janu‐ ary 1995 to December 2010. Last observations were made in December 2004 for the CYC group and December 2010 for the ETN group. Vales are represented by mean (S.D.) unless otherwise noted. Causes of death of patients who died during the study, and these causes were most closely related to their death. 2)CYC was given until December, 2004. Thirty-six alive [8 males, 28 females; mean (S.D.) age = 65.7 (10.8) years] and 26 dead [3 males, 23 females; mean (S.D.) age = 71.9 (8.5) years]. CYC was treated according to the level of 24-h Ccr: Ccr≧80 (ml/min): 100 (mg/day), 60≦Ccr < 80 (ml/min): 75 (mg/day), 40≦Ccr < 60 (ml/min): 40 (mg/day), 10≦Ccr < 20 (ml/min): 25 (mg/day), Ccr < 10 (ml/ min): 20 (mg /day). 3)ETN was until December, 2010. Sixteen alive [3 males, 13 females; mean (S.D.) age = 64.2 (8.5) years] and 8 dead [1 male, 7 females; mean (S.D.) age = 66.0 (7.8) years]. 4)Student's-*t* analysis was performed to com‐ pare CYC and ETN, with P < 0.05 indicating a significant result. 5)Stenbrocher'scalassification according to JAMA 1949; 140: 659-62.Quoted from Reference No. 75.

**Table 7.** Clinical characteristics and laboratory findings of patients1)

of effects of groups (SAA1.3 or treatments) on changes in individual markers. Findings were statistically significant at *P*<0.05. We used SPSS Statistics 17.0, Base and Advanced (SPSS Inc,

Table 7 provides patients' clinical characteristics and laboratory findings. Despite treatments being administered during different periods, clinical and laboratory findings of both groups were quite similar at the start of each treatment, except for the SAA1.3 genotype and dura‐ tion AA amyloidosis since diagnosis (*P*=0.015 and *P*<0.001, respectively). With regard to bio‐ markers indicating renal dysfunction, ETN had worse kidney damage than did CYC. During the study, patients died in each treatment group at the almost same rate. In the CYC group, congestive heart failure and infectious pneumonia occurred frequently. Patients giv‐ en ETN had a lower rate of congestive heart failure as cause of death, suggesting of the pos‐

Years since RA onset and years since diagnosis of AA amyloidosis were significantly differ‐ ent for SAA1.3 homozygosity *vs* other genotypes (15.6±7.8 *vs* 21.4±9.9, *P*=0.046, and 7.44±4.9 *vs* 9.7±4.5, *P*=0.016, respectively). Comparison of CRP, Alb, eGFR, and Crea for both groups at initial and final observations, disregarding SAA1.3 allele polymorphisms, showed that ETN reduced serum CRP levels and increased serum Alb levels more than did CYC (ETN *vs* CYC: CRP: from 4.7±0.8 to 0.5±0.3 mg/dl *vs* from 4.0±1.6 to 2.8±1.2 mg/dl, *P*<0.01; Alb: from 2.6±0.4 to 3.5±0.4 g/dl *vs* from 2.8±0.3 to 2.8±0.5 g/dl, *P*<0.01, respectively). Thus, ETN signifi‐ cantly improved serum CRP and Alb levels and was clearly more effective than CYC. CRP and Alb interactions with polymorphism (homozygous for SAA1.3 or other polymorphisms) showed no significance (*P*=0.777 and *P*=0.715, respectively), but CRP and Alb interactions with treatment (ETN or CYC) demonstrated significant results (both *P*<0.01). Within-subject analysis showed that treatments improved eGFR: ETN: from 21.8±18.9 to 24.9±18.7 ml/min/

eGFR being significant (*P*=0.032). ETN increased eGFR, thus improving the decreased renal function caused by AA amyloidosis, more than did CYC (Fig. 9A), but this effect was not related to SAA1.3 allele polymorphisms (Fig. 9B). Neither treatment affected Crea levels. SAA1.3 allele did not affect treatment in both groups of patients, as evidenced by interac‐ tions of SAA1.3 allele with CRP, Alb, eGFR, and Crea (*P*=0.777, *P*=0.715, *P*=0.465, and

Because ETN was more effective than CYC, according to CRP, Alb, and eGFR measures, we calculated the hazard ratio between ETN and CYC as a survival parameter. According to Cox proportional hazards survival analysis, ETN significantly improved survival (*P*=0.025). Also, the Kaplan-Meier curves showed a significant difference between ETN and CYC (Fig. 10). The hazard ratio for ETN evidenced significant results for the risk of death endpoint (eGFR: *P*=0.024 and 24-hour proteinuria: *P*=0.025, respectively) but CYC

, *P*=0.035, with ETN's effect on

Chicago, IL, USA) for statistical analyses.

sibility of an inhibitory effect on progressive heart failure.

1.73m2 *vs* CYC: from 29.3±12.7 to 18.6±9.3 ml/min/1.73m2

*P*=0.228, respectively).

did not (Table 8).

**5.2. Results**

228 Amyloidosis

**eGFR 24-Hour proteinuria**

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

**Hazard ratio (95% confidence interval)**

> 1.779 (1.074-2.946)

> 1.161 (0.542-2.488)

**P-value**

http://dx.doi.org/10.5772/53801

231

0.025

0.701

**P-value**

0.024

0.110

Hazard ratio for each treatment using the Cox proportional hazards models to assess effect of treatments on the risk of death as the endpoint, being determined by two variables, eGFR and 24-h proteinuria. Quoted and modified from Reference No. 75. ETN: etanercept, CYC: cyclophosphamide, eGFR: estimated

The goal of AA amyloidosis therapy is control of the underlying disorder. Treatment sup‐ pressing inflammatory activity reduces circulatory levels of SAA, an acute-phase reactant. In AA amyloidosis secondary to RA, treatment has focused on using cytotoxic drugs such as CYC and chlorambucil [29, 32] and more recently on TNFα inhibitors and IL-6 receptor anti‐ body [45,56]. Before the advent of biologics, encouraging reports of alkylating agents as ben‐ efiting RA patients with AA amyloidosis were published. The rationale of this treatment seems to be similar to autologous stem cell transplantation, which generates new self-toler‐ ant lymphocytes after alkylating agent treatment by eliminating self-reactive lymphocytes [78]. In the light of the reported superiority of CYC compared with MTX for managing RA patients with AA amyloidosis [9], using alkylating agents may improve AA amyloidosis. Cytotoxic drugs and cytokine inhibitors affect AA amyloid deposits by suppressing SAA production. Also, anti-TNFα therapies, by inhibiting expression of receptors of advanced glycation end-products (RAGE), may reduce interactions between AA amyloid fibrils and RAGE and thereby prevent AA-mediated cell toxicity [79, 80]. Thus, our findings that ETN had greater effects on AA amyloidosis secondary to RA than did CYC was not unexpected, and early therapeutic intervention in RA may avoid the complication of AA amyloidosis by

In Japan, use of MTX to treat with RA patients was permitted in 1999, the maximum dose being 8 mg/week, until February 2011; use of ETN was allowed in 2005. In our study the time from diagnosis of AA amyloidosis was shorter for the CYC group than the ETN group (Table 8), but treatment strategies and DMARDs used were the same, except for the use of biologics. Although MTX is now considered an anchor drug for RA treatment, it was used infrequently for AA amyloidosis patients because of its renal damage. No significant differ‐ ences between groups in MTX therapy were found (Table 7). The recovery of Alb biosynthe‐ sis, improved acute-phase response, and ameliorated eGFR are all demonstrable endpoints, and we suggest that Alb reflects the severity of AA amyloidosis. We found that the different therapies rather than SAA1.3 allele polymorphism influenced changes in CRP and Alb. Al‐

**Hazard ratio (95% confidence interval)**

> 0.949 (0.907-0.993)

> 0.951 (0.894-1.012)

ETN

CYC

**5.3. Discussion**

glomerular filtration rate.

**Table 8.** Hazard ratio for each treatment

controlling rheumatoid disease activity [26].

**Figure 9.** A) Changes in eGFR between initial- and last-visit as an effect of treatment (ETN or CYC). (B) Changes in eGFR between initial- and last-visit as an effect of SAA1.3 allele genotype (homozygosity or other polymorphisms). Quoted and modified from Reference No. 75.

**Figure 10.** Kaplan-Meier survival curves after treatment with ETN (continuous line) and CYC (dotted line; P=0.025, logrank test). Quoted and modified from Reference No. 75.


Hazard ratio for each treatment using the Cox proportional hazards models to assess effect of treatments on the risk of death as the endpoint, being determined by two variables, eGFR and 24-h proteinuria. Quoted and modified from Reference No. 75. ETN: etanercept, CYC: cyclophosphamide, eGFR: estimated glomerular filtration rate.

**Table 8.** Hazard ratio for each treatment

#### **5.3. Discussion**

**Figure 9.** A) Changes in eGFR between initial- and last-visit as an effect of treatment (ETN or CYC). (B) Changes in eGFR between initial- and last-visit as an effect of SAA1.3 allele genotype (homozygosity or other polymorphisms).

**Figure 10.** Kaplan-Meier survival curves after treatment with ETN (continuous line) and CYC (dotted line; P=0.025, log-

Quoted and modified from Reference No. 75.

230 Amyloidosis

rank test). Quoted and modified from Reference No. 75.

The goal of AA amyloidosis therapy is control of the underlying disorder. Treatment sup‐ pressing inflammatory activity reduces circulatory levels of SAA, an acute-phase reactant. In AA amyloidosis secondary to RA, treatment has focused on using cytotoxic drugs such as CYC and chlorambucil [29, 32] and more recently on TNFα inhibitors and IL-6 receptor anti‐ body [45,56]. Before the advent of biologics, encouraging reports of alkylating agents as ben‐ efiting RA patients with AA amyloidosis were published. The rationale of this treatment seems to be similar to autologous stem cell transplantation, which generates new self-toler‐ ant lymphocytes after alkylating agent treatment by eliminating self-reactive lymphocytes [78]. In the light of the reported superiority of CYC compared with MTX for managing RA patients with AA amyloidosis [9], using alkylating agents may improve AA amyloidosis. Cytotoxic drugs and cytokine inhibitors affect AA amyloid deposits by suppressing SAA production. Also, anti-TNFα therapies, by inhibiting expression of receptors of advanced glycation end-products (RAGE), may reduce interactions between AA amyloid fibrils and RAGE and thereby prevent AA-mediated cell toxicity [79, 80]. Thus, our findings that ETN had greater effects on AA amyloidosis secondary to RA than did CYC was not unexpected, and early therapeutic intervention in RA may avoid the complication of AA amyloidosis by controlling rheumatoid disease activity [26].

In Japan, use of MTX to treat with RA patients was permitted in 1999, the maximum dose being 8 mg/week, until February 2011; use of ETN was allowed in 2005. In our study the time from diagnosis of AA amyloidosis was shorter for the CYC group than the ETN group (Table 8), but treatment strategies and DMARDs used were the same, except for the use of biologics. Although MTX is now considered an anchor drug for RA treatment, it was used infrequently for AA amyloidosis patients because of its renal damage. No significant differ‐ ences between groups in MTX therapy were found (Table 7). The recovery of Alb biosynthe‐ sis, improved acute-phase response, and ameliorated eGFR are all demonstrable endpoints, and we suggest that Alb reflects the severity of AA amyloidosis. We found that the different therapies rather than SAA1.3 allele polymorphism influenced changes in CRP and Alb. Al‐ so, eGFR may reflect diminished renal blood flow, and only ETN improved eGFR, thus indi‐ cating better renal function and greater efficacy of ETN than CYC (Fig. 9A). We found no evidence linking SAA1.3 allele to treatment efficacy (Fig. 9B).

**References**

[1] Westermark GT, Westermark P: Serum amyloid A and protein AA: molecular mech‐

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

233

[2] Westermark P, Lundmark K, Westermark GT: Fibrils from designed non- amyloidrelated synthetic peptides induce AA-amyloidosis during inflammation in an animal

[3] Larsson A, Malmstrom S, Westermark P: Signs of cross-seeding: aortic medin amy‐

[4] Obici L, Raimondi S, Lavatell F, Bellotti V, Merlini G: Susceptibility to AA amyloido‐ sis in rheumatic diseases: a critical overview. Arthritis Rheum (Arthritis Care Res)

[5] Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M: Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 408-13. [6] Nakamura T: Amyloid A amyloidosis secondary to rheumatoid arthritis: an uncom‐

[7] Okuda Y, Takasugi K: Successful use of a humanized anti-interleukin-6 receptor anti‐ body, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic

[8] Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S, et al : Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroin‐ testinal mucosal amyloid deposits in reactive amyloidosis associated with

[9] Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M: Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheuma‐

[10] Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M: Etanercept can induce res‐ olution of renal deterioration in patients with amyloid A amyloidosis secondary to

[11] Nakamura T, Higashi S, Tomoda K, Tsukano M, Arizono K, Nakamura T: Etanercept treatment in patients with rheumatoid arthritis on dialysis. Rheumatol Int 2010; 30:

[12] Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al: A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Gen‐

[13] Moriguchi M, Terai C, Kosei Y, Uesato M, Nakajima A, Inada S, et al: Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent peri‐

anisms of a transmissible amyloidosis. FEBS Lett 2009; 583: 2685-90.

loid as a trigger for protein AA deposition. Amyloid 2011; 18: 229-34.

mon yet important complication. Curr Rheumatol Rev 2007; 3: 231-41.

arthritis. Arthritis Rheum 2006; 54: 2997-3000.

rheumatoid arthritis. J Rheumatol 2009; 36: 2409-15.

toid arthritis. Rheumatology (Oxford) 2006; 45: 43-9.

rheumatoid arthritis. Clin Rheumatol 2010; 29: 1395-401.

model. PLoS One 2009; 4: e6041.

2009; 61: 1435-40.

1527-8.

et 1995; 4: 1083-7.

## **6. Conclusion**

Although significant advances have been made in understanding of the pathology, pathogene‐ sis, and clinical treatment of AA amyloidosis secondary to RA, the disease is still an important complication that warrants further investigation. The SAA1.3 allele serves not only as a risk factor for AA amyloidosis but also as a factor related to poor prognosis and shortened survival in Japanese patients with RA, and understanding both disorders would benefit from investiga‐ tion of the SAA1.3 allele. AA amyloidosis secondary to RA is now clearly influenced by many variables, and clinical pictures differ among patients. The pathological process in RA patients with AA amyloidosis seems to be more complicated and subtle than previously realized. Clari‐ fication of the formation and degeneration or turnover of AA amyloid fibrils and elucidation of the biological contributions of SAA in health and disease are indispensable prerequisites to the management of AA amyloidosis secondary to RA. By employing with the newly developed therapies, AA amyloidosis secondary to RA will already become both treatable and curable disease. Further, genetic predisposition, SAA1.3 allele genotype, would serve one of personal‐ ized medicines to make AA amyloidosis secondary to RA a preventable disease.

## **Acknowledgements**

The author would like to thank his colleagues Shin-ya Hirata, MD, PhD, Hirokazu Takaoka, MD, Syu-ichi Higashi, MD, PhD, Hironori Kudoh, MD, PhD, Kunihiko Tomoda, MD, PhD, Michishi Tsukano, MD, PhD, Satoshi Baba, MD, PhD, and Masahiro Shono, MD, PhD, for their collabora‐ tions and contributions to this work. This work was supported in part by a Grant-in-Aid for sci‐ entific research from the Japanese Ministry of Health, Labor, and Welfare and the Amyloidosis Research Committee for Intractable Diseases, Epochal Diagnosis, and Treatment in Japan.

### **Author details**

Tadashi Nakamura

Address all correspondence to: nakamura@k-shinto.or.jp

Section of Clinical Rheumatology, Kumamoto Shinto General Hospital and Graduate School of Medical Sciences, Kumamoto University, Japan

The author has declared no conflicts of interest.

## **References**

so, eGFR may reflect diminished renal blood flow, and only ETN improved eGFR, thus indi‐ cating better renal function and greater efficacy of ETN than CYC (Fig. 9A). We found no

Although significant advances have been made in understanding of the pathology, pathogene‐ sis, and clinical treatment of AA amyloidosis secondary to RA, the disease is still an important complication that warrants further investigation. The SAA1.3 allele serves not only as a risk factor for AA amyloidosis but also as a factor related to poor prognosis and shortened survival in Japanese patients with RA, and understanding both disorders would benefit from investiga‐ tion of the SAA1.3 allele. AA amyloidosis secondary to RA is now clearly influenced by many variables, and clinical pictures differ among patients. The pathological process in RA patients with AA amyloidosis seems to be more complicated and subtle than previously realized. Clari‐ fication of the formation and degeneration or turnover of AA amyloid fibrils and elucidation of the biological contributions of SAA in health and disease are indispensable prerequisites to the management of AA amyloidosis secondary to RA. By employing with the newly developed therapies, AA amyloidosis secondary to RA will already become both treatable and curable disease. Further, genetic predisposition, SAA1.3 allele genotype, would serve one of personal‐

ized medicines to make AA amyloidosis secondary to RA a preventable disease.

The author would like to thank his colleagues Shin-ya Hirata, MD, PhD, Hirokazu Takaoka, MD, Syu-ichi Higashi, MD, PhD, Hironori Kudoh, MD, PhD, Kunihiko Tomoda, MD, PhD, Michishi Tsukano, MD, PhD, Satoshi Baba, MD, PhD, and Masahiro Shono, MD, PhD, for their collabora‐ tions and contributions to this work. This work was supported in part by a Grant-in-Aid for sci‐ entific research from the Japanese Ministry of Health, Labor, and Welfare and the Amyloidosis Research Committee for Intractable Diseases, Epochal Diagnosis, and Treatment in Japan.

Section of Clinical Rheumatology, Kumamoto Shinto General Hospital and Graduate School

evidence linking SAA1.3 allele to treatment efficacy (Fig. 9B).

**6. Conclusion**

232 Amyloidosis

**Acknowledgements**

**Author details**

Tadashi Nakamura

Address all correspondence to: nakamura@k-shinto.or.jp

of Medical Sciences, Kumamoto University, Japan

The author has declared no conflicts of interest.


od of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999; 105: 360-6.

[28] Nakamura T: Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysi‐

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

235

[29] Keysser G, Keysser C, Keysser M: Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term follow-up of 108 patients. Z Rheumatol

[30] Berglund K, Keller C, Thysell H: Alkylating cytostatic treatment in renal amyloidosis

[31] Ahlmen M, Ahlmen J, Svalander C, Bucht H: Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin

[32] Berglund K, Thysell H, Keller C: Results, principles and pitfalls in the management of renal AA-amyloidosis: a 10-21 year followup of 16 patients with rheumatic disease

[33] Chevrel G, Jenvrin C, McGregor B, Miossec P: Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment

[34] Shapiro DL, Spiera H: Regression of the nephritic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum 1995; 38:

[35] Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S: Efficacy of cy‐ clophosphamide combined with prednisolone in patients with AA amyloidosis sec‐

[36] Kishimoto T, Akira S, Taga T: IL-6 receptor and mechanism of signal transduction.

[37] Hirano T, Ishihara K, Hibi M: Roles of STAT3 in mediating the cell growth, differen‐ tiation and survival signals relayed through the IL-6 family of cytokine receptors.

[38] Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, et al: Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

[39] Ueda M, Ando Y, Nakamura M, Yamashita T, Himeno S, Kim J, et al: FK506 inhibits murine AA amyloidosis: possible involvement of T cells in amyloidogenesis. J Rheu‐

[40] Kogina K, Shoda H, Yamaguchi Y, Tsuno NH, Takahashi K, Fujio K, et al: Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4+

[41] Pettersson T, Konttinen YT, Maury CPJ: Treatment strategies for amyloid A amyloi‐

T cells.

secondary to rheumatoid arthritis. Ann Rheum Dis 1987; 46: 757-62.

treated with alkylating cytostatics. J Rheumatol 1993; 20: 2051-7.

ondary to rheumatoid arthritis. Clin Rheumatol 2003; 22: 371-5.

Int J Immunopharmacol 1992; 14: 431-8.

Oncogene 2000; 19: 2548-56.

Gene Cells 2005; 10: 1051-63.

matol 2006; 33: 2260-70.

Mol Cells 2009; 28: 125-30.

dosis. Expert Opin Pharmacother 2008; 9: 2117-28.

with pulse cyclophosphamide. Rheumatology (Oxford) 2001; 40: 821-5.

ology and treatment. Clin Exp Rheumatol 2011; 29: 850-7.

1998; 57: 101-7.

1851-4.

Rheumatol 1987; 6: 27-38.


[28] Nakamura T: Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysi‐ ology and treatment. Clin Exp Rheumatol 2011; 29: 850-7.

od of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet

[14] Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB: SAA1 alleles as risk fac‐

[15] Nakamura T, Tomoda K,, Tsukano M,, Yamamura Y, Baba S: Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid ar‐

[16] Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Baba S: Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis: three case reports. Clin

[17] Hawkins PN, Pepys MB: Imaging amyloidosis with radiolabelled SAP. Eur J Nucl

[18] Tennent GA, Lovat LB, Pepys MB: Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl

[19] Hawkins PN: The diagnosis, natural history and treatment of amyloidosis. The Goul‐

[21] Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN: Amyloid load and clini‐ cal outcome in AA amyloidosis in relation to circulating concentration of serum amy‐

[22] Wakhlu A, Krisnani N, Hissatia P, Aggarwal A, Misra R: Prevalence of secondary amyloidosis in Asian north Indian patients with rheumatoid arthritis. J Rheumatol

[23] Laiho K, Tiitinen S, Kaarela K, Helin H, Isomaki H: Secondary amyloidosis has de‐ creased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999;

[24] Kaipiainen-Seppanen O, Myllykangas-Luosujarvi R, Lampainen E, Ikaheimo R: In‐ tensive treatment of rheumatoid arthritis reduces need for dialysis due to secondary

[25] Hanzenberg BPC, van Rijswijk MH:. Where has secondary amyloidosis gone? Ann

[26] Nakamura T: Clinical strategies for amyloid A amyloidosis secondary to rheumatoid

[27] David J, Vouyiouka O, Ansell BM, Hall A, Woo P: Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993; 2: 85-90.

stonian Lecture 1995. J R Coll Physicians Lond 1997; 31: 552-60.

[20] Pepys MB: Science and serendipity. Clin Med 2007; 7: 562-78.

tors in reactive systemic AA amyloidosis. Amyloid 1998; 5: 262-5.

thritis. Mod Rheumatol 2004; 14: 498-501.

Exp Rheumatol 2003; 21: 673-4.

Acad Sci USA 1995; 92: 4299-303.

loid A protein. Lancet 2001; 358: 24-9.

amyloidosis. Scand J Rheumatol 2000; 29: 232-5.

arthritis. Mod Rheumatol 2008; 18: 109-18.

Med 1995; 22: 595-9.

2003; 30: 948-51.

Rheum Dis 2000; 59: 577-9.

18: 122-3.

1999; 105: 360-6.

234 Amyloidosis


[42] Dember LM: Modern treatment of amyloidosis: unresolved questions. J Am Soc Nephrol 2009; 20: 469-72.

body: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

237

[55] Hagiwara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K: Il-6 plays a crit‐ ical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform realtime quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314:

[56] Hattori Y, Ubara Y, Simida K, Hiramatsu R, Hasegawa E, Yamanouchi M, et al: Toci‐ lizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis

[57] Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, et al: Rapid im‐ provement of AA amyloidosis with humanized anti-interleukin 6 receptor antibody

[58] Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S: Discon‐ nect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic

[59] Rubbert-Roth A, Finckh A: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;

[60] Narvaez J, Hernandes MV, Ruiz JM, Vaqueero CG, Juanola X, Nollaa JM: Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis. Joint Bone Spine

[61] Smith JW, McDonald TL: Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned me‐

[62] Migita K, Yamasaki K, Shibatomi H, Ida H, Kita M, Kawakami A, et al: Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes.

[63] Nakamura T, Baba S, Yamamura Y, Tsuruta T, Matsubara S, Tomoda K, et al: Com‐ bined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1γ/γ genotype in a patient with rheumatoid arthritis. Mod

[64] Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S: Efficacy of cy‐ clophosphamide combined with prednisolone in patients with AA amyloidosis sec‐

[65] Matsuda M, Morita H, Ikeda S: Long-term follow-up of systemic reactive AA amyloi‐ dosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose

dia: the effects of prednisolone. Clin Exp Immunol 1992; 90: 293-9.

ondary to rheumatoid arthritis. Clin Rheumatol 2003; 22: 371-5.

secondary to rheumatoid arthritis. Amyloid 2012; 19: 37-40.

and patient outcomes. Arthritis Rheum 2006; 54: 3119-25.

treatment. Ann Rheum Dis 2009; 68: 1235-6.

1761-9.

363-9.

11(Suppl. 1): S1.

2011; 78: 98-101.

Clin Exp Immunol 2001; 123: 408-11.

corticosteroid. Intern Med 2002; 41: 403-7.

Rheumatol 2000; 10: 160-4.


body: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-9.

[55] Hagiwara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K: Il-6 plays a crit‐ ical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform realtime quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314: 363-9.

[42] Dember LM: Modern treatment of amyloidosis: unresolved questions. J Am Soc

[43] Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M: Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol 2010;

[44] Masutani K, Nagata M, Ikeda H, Takeda K, Katafuchi R, Hirakata H, et al: Glomeru‐ lar crescent formation in renal amyloidosis. A clinicopathological study and demon‐ stration of upregulated cell-mediated immunity. Clin Nephrol 2008; 70: 464-74. [45] Kuroda T, Ootaki Y, Sato H, Fujimura T, Nakatsue T, Murakami S, et al: A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with inflixi‐

[46] Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D: Rapid and complete reso‐ lution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis

[47] Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al: Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

[48] Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S: Efficacy of eternercept in pa‐ tients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol

[49] Ishii W, Kishida D, Suzuki A, Shimojima Y, Matsuda M, Hoshii Y, et al: A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduadenal mucosa after a combination therapy of cor‐

[50] Smith GR, Tymms KE, Falk M: Etanercept treatment of renal amylopidosis complain‐

[51] Fernandes-Nebro A, Torero E, Ortiz-Santamaria V, Castro MC, Olive A, et al: Treat‐ ment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis

[52] Roque R, Ramiro S, Corderio A, Goncalves P, Canas SD, Santos M: Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents. Clin

[53] Nobre CA, Callado MRM, Rodriges CEM, de Menezes DB, Vieira WP : Anti-TNF therapy in renal amyloidosis in refractory rheumatoid arthritis: a new therapeutic

[54] Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor anti‐

using tumor necrosis factor alpha antagonists. Am J Med 2003; 115: 589-90.

treated with infliximab. Arthritis Rheum 2002; 46: 2571-3..

ticosteroid and etanercept. Rheumatol Int 2011; 31; 247-50.

ing rheumatoid arthritis. Intern Med 2004; 34: 570-2.

perspective. Bras J Rheumatol 2010; 50: 205-10.

Nephrol 2009; 20: 469-72.

mab. Rheumatol Int 2008; 28: 1155-9.

Arthritis Rheum 2003; 48: 2019-24.

Rheumatol 2011; 30: 869-70.

2007; 25: 518-22.

6: 417-29.

236 Amyloidosis


[66] Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K, et al: Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloido‐ sis, successfully treated with corticosteroid and octreotide. Amyloid 2005; 12: 48-53.

[79] Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor kB, and 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 33: 25781-90.

Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis

http://dx.doi.org/10.5772/53801

239

[80] Okamoto M, Katagiri Y, Kiire A, Momohara S, Kamatani M: Serum amyloid A acti‐ vates nuclear factor kB in rheumatoid synovial fibroblasts through binding to recep‐

tor of advanced glycation end-products. J Rheumatol 2008; 35: 752-6.


[79] Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor kB, and 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000; 33: 25781-90.

[66] Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K, et al: Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloido‐ sis, successfully treated with corticosteroid and octreotide. Amyloid 2005; 12: 48-53.

[67] Bakker M, Jacobs JWG, Welsing PMJ, Verstappen SMM, Tekstra J, Ton E, et al: Lowdose prednisolone inclusion in a methotrexate-based, tight control strategy for early

[68] Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, et al: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;

[69] Noborn F, O'Callaghan P, Hermansson E, Zharng X, Ancsin JB, Damas AM, et al: Heparan sulfate/heparin promotes transthyretin fibrillization through selective bind‐

[70] Pepys MB, Herbert J, Hutchinson L, Tennent GA, Lachmann HJ, Gallimore JR, et al: Targeted pharmacological depletion of serum amyloid P component for treatment of

[71] Santos NC, Figueria-Coelho J, Martins-Silva J, Saldanha C: Multidisciplinary utiliza‐ tion of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Bio‐

[72] Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, et al: Oral dimethyl sulf‐ oxide for systemic amyloid A amyloidosis complication in chronic inflammatory dis‐

[73] Kuroda T, Tanabe N, Sato H, Ajiro J, Wada Y, Murakami S, et al: Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment.

[74] Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA: The pharmacokinet‐ ics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm

[75] Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M: Effectiveness of etaner‐ cept vs cyclophosphamide as treatment for patients with amylopid A amyloidosis

[76] Maury CPJ, Teppo A-M: Mechanism of reduced amyloid-A-degrading activity in se‐

[77] Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-92.

[78] Shapiro DL, Spiera H: Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum 1995; 38:

secondary to rheumatoid arthritis. Rheumatology (Oxford) 2012; 51: 2064-9.

rum of patients with secondary amyloidosis. Lancet 1982; 2: 234-7.

ease: a retrospective patient chart review. J Gastroenterol 2006; 41: 444-9.

ing to a basic motif in the protein. Proc Natl Acad Sci USA 2011; 108: 5584-9.

human amyloidosis. Nature 2002; 417: 254-9.

chem Pharmacol 2003; 65: 1035-41.

Rheumatol Int 2006; 26: 1147-53.

Pharmacol 2005; 57: 1407-13.

1851-4.

rheumatoid arthritis. A randomized trial. Ann Intern Med 2012; 156: 326-39.

356: 2349-60.

238 Amyloidosis

[80] Okamoto M, Katagiri Y, Kiire A, Momohara S, Kamatani M: Serum amyloid A acti‐ vates nuclear factor kB in rheumatoid synovial fibroblasts through binding to recep‐ tor of advanced glycation end-products. J Rheumatol 2008; 35: 752-6.

## *Edited by Dali Feng*

Amyloidosis is an uncommon disorder characterized by the deposition of extracellular amyloid proteins in tissues. Significant advancement has been made recently, which not only provides insight in to the pathophysiology of the disease but also helps to discover new therapies to fight the deadly disease. If accurate diagnosis and typing are made early, effective or even curative therapies are available. Unfortunately, because of the rarity of the disease and its protean clinical manifestations, patients may be misdiagnosed, especially at early stage of the disease, and this could lead to missed opportunities to effective therapy. The aim of the book is to help readers become familiar with the clinical presentation of amyloidosis and to review the latest diagnostic and therapeutic development.

Photo by Leonid Andronov / iStock

Amyloidosis

Amyloidosis